Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

September 30, 2011

Conditions
Chronic Hepatitis C, Genotype 1
Interventions
DRUG

Peg-interferon-alfa2a (Pegasys)

Peg-interferon-alfa2a 180 µg per week

DRUG

Ribavirin (Copegus)

Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg

Trial Locations (1)

41346

Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Sodra Alvsborgs Hospital

OTHER

collaborator

Skaraborg Hospital

OTHER_GOV

collaborator

Uddevalla Hospital

UNKNOWN

collaborator

Skane University Hospital

OTHER

collaborator

Lund University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Göteborg University

OTHER

NCT00910975 - Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C | Biotech Hunter | Biotech Hunter